Merck stock forecast
Merck’s weighted forecast is $131.92 in October 2027, a 7% loss with dividends. It hinges on whether newer products replace enough KEYTRUDA revenue before biosimilar erosion.
Where could Merck's shares go?
The probability-weighted forecast points to a lower total return at every date. It puts October 2027 at $131.92, a 7% loss with dividends. October 2028 reaches $129.25, a 6% loss. By October 2029, the value is $106.83, a 19% loss.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 30 % | 105.78 (-25 %) | 84.98 (-37 %) | 58.31 (-53 %) |
| Base | 50 % | 136.43 (-4 %) | 135.06 (-2 %) | 110.98 (-16 %) |
| Bull | 20 % | 159.87 (+12 %) | 181.12 (+29 %) | 169.24 (+24 %) |
| Weighted | 100 % | 131.92 (-7 %) | 129.25 (-6 %) | 106.83 (-19 %) |
What has to go right or wrong for Merck?
Earnings create the central risk because KEYTRUDA and QLEX represented about half of 2025 sales, while biosimilar competition is expected between 2028 and 2029. The base case uses $21,600M at the first date. It rises to $22,032M before easing to $20,071M at the last date.
The bear case falls to $20,017M and then $19,028M before reaching $16,000M. Weak Gardasil demand, limited launch replacement and faster KEYTRUDA erosion explain the declining margins. The bull case reaches $23,016M, then $24,480M, before easing to $24,090M. QLEX, newer launches and vaccine recovery must create operating leverage for that path.
| October 2027 | October 2028 | October 2029 | |
|---|---|---|---|
| Earnings | 21,600 (20,017 / 23,016) | 22,032 (19,028 / 24,480) | 20,071 (16,000 / 24,090) |
| Shares (millions) | 2,454 (2,460 / 2,448) | 2,447 (2,463 / 2,433) | 2,442 (2,470 / 2,420) |
| Dividends per share | 3.55 (3.40 / 3.60) | 3.75 (3.40 / 3.80) | 3.95 (3.40 / 4.00) |
| Price to earnings | 15.50 (13.00 / 17.00) | 15.00 (11.00 / 18.00) | 13.50 (9.00 / 17.00) |
How much cash does Merck really make?
Working-capital movements absorbed $6,976 million in 2025. Capital spending also rose to $4,112 million, although public figures do not show how much maintained existing capacity or expanded it. Stock compensation consumed no immediate cash, but it diluted shareholders; deducting its $820 million expense produces an analytical “real” free cash flow.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 16,472 | 21,468 | 13,006 | 19,095 | 13,122 |
| − Capital spending | 4,112 | 3,372 | 3,863 | 4,388 | 4,448 |
| = Free cash flow | 12,360 | 18,096 | 9,143 | 14,707 | 8,674 |
| − Stock pay | 820 | 761 | 645 | 541 | 479 |
| = Real free cash flow | 11,540 | 17,335 | 8,498 | 14,166 | 8,195 |
| Real free cash flow, % of revenue | 17.8% | 27.0% | 14.1% | 23.9% | 16.8% |
What does an investor pay for Merck?
The wide gap between trailing and forward P/E, or price divided by earnings, is therefore mainly a warning about the denominator. Acquisition charges depressed recent profit, while the forward measure assumes improvement. Removing a charge from adjusted earnings does not restore the cash spent or cancel the debt.